title: For how long should osteoporosis treatment continue?
abstract: Studies on the most effective of the commonly used bone-specific drugs, the antiresorptives zoledronic acid and denosumab, as well as up-to-date menopausal hormone therapy for early prevention refer to sound long-term safety data. However, depending on both the patient's characteristics and the properties of the respective regimens, the rates of side-effects, tolerability and persistence differ substantially. They are crucial limiting factors for actual efficacy in the clinical setting and thus determine the length and continuation of treatment.
authors.affiliation: a KLIMAX Menopause and Osteoporosis Clinic , Vienna , Austria.
authors.forename: E
authors.initials: E
authors.lastname: Boschitsch
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D000069448:Denosumab / Q000008:administration & dosage*; D004164:Diphosphonates / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000517:prevention & control; D013997:Time Factors; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000069448:Denosumab; D000077211:Zoledronic Acid
keywords: DENOSUMAB; EFFICACY; MENOPAUSAL HORMONE THERAPY; PERSISTENCE; SAFETY; ZOLEDRONIC ACID